Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lateral Flow-Based Antibody Test Developed for Trachoma

By LabMedica International staff writers
Posted on 24 Aug 2016
Trachoma, resulting from repeated infection with the bacterium Chlamydia trachomatis, is the leading global infectious cause of blindness and blinding trachoma as a public health problem is targeted for elimination by 2020.

A lateral flow-based assay (LFA) has been developed for the detection of antibodies against immunodominant antigen Pgp3 from Chlamydia trachomatis, the causative agent of urogenital chlamydia infection and ocular trachoma.

Scientists at the IHRC, Inc., (Centers for Disease Control and Prevention, Atlanta, GA, USA) and their colleagues collected serum samples from a community in Nepal in 2000, 2002, or 2014 as part of a study of trachoma post-mass drug administration sero-surveillance. More...
There were 432 Nepalese whose ages ranged from 1to 90 years in the cohort. Additional samples from around the world were also collected including dried blood spots from 1 to 9 year olds in Tanzania, from which serum was eluted.

The lateral flow assay was prepared using conjugate reagents and capture reagents were prepared with optimal conditions. For the capture reagents, 1.5 mg/mL of Pgp3 protein and biotinylated bovine serum albumin were dispensed onto the test and control lines, respectively, of a nitrocellulose membrane at a rate of 0.1 μL/mm using an IsoFlow Dispenser (Imagene Technology, Hanover, NH, USA). The detection reagent or conjugate was prepared by conjugating Pgp3 to InnovaCoat Gold (Innova Biosciences, Cambridge, UK).

The investigators found that the optimization of Pgp3 concentration on the test line and capture reagents conjugated to colloidal gold using positive controls showed the strongest test line signal with the combination of Pgp3-colloidal gold and 1.5 mg/mL of Pgp3 as the capture reagent. The LFA yielded positive signals with serum and whole blood, but not with eluted dried blood spots. For serum, the agreement of the LFA with the non-reference multiplex assay was 96%, the specificity using non-endemic pediatric sera was 100%, and the inter-rater agreement was very high. For whole blood, the agreement of LFA with multiplex was 81.5%, the specificity was 100%, and the inter-rater agreement was also high. The LFA was tested in a field environment and yielded similar results to those from laboratory-based testing.

The authors concluded that their results show the successful development of a lateral flow assay for detection of antibodies against Pgp3 with reliable use in field settings, which would make antibody-based testing for trachoma surveillance highly practical, especially after cessation of trachoma elimination programs. The study was published in the August 2016 issue of the Journal of Immunological Methods.

Related Links:
IHRC
Imagene Technology
Innova Biosciences

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.